澳大利亚生物制药公司 LTR Pharma（ASX:LTP）宣布，其鼻喷型勃起功能障碍（ED）治疗药物 SPONTAN® 的临床研究成果，正式发表在国际药学权威期刊《欧洲药物科学杂志》。

研究数据显示，SPONTAN® 的平均起效时间为 12分钟，远快于传统口服片剂的 56分钟，最快可实现 5倍起效速度提升。尽管剂量为口服片的一半，SPONTAN® 展现出更高的吸收效率，并具备约 4小时 的持续疗效和良好的安全性。

LTR Pharma 首席医疗官 Geoff Strange 教授表示, SPONTAN® 为ED治疗带来了显著进步，解决了患者普遍关注的起效慢、缺乏自发性等问题。

目前，SPONTAN® 已通过澳大利亚TGA特别获取计划（SAS）提供使用，目前在推进美国及其他市场的注册申请。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.